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ARTICLE
Polymorphism in a lincRNA Associates
with a Doubled Risk of Pneumococcal Bacteremia
in Kenyan Children
The Kenyan Bacteraemia Study Group, Wellcome Trust Case Control Consortium 2 (WTCCC2),
Anna Rautanen,1,29,30,* Matti Pirinen,1,29 Tara C. Mills,1 Kirk A. Rockett,1,2 Amy Strange,1
Anne W. Ndungu,1 Vivek Naranbhai,1 James J. Gilchrist,1,3 Ce´line Bellenguez,1 Colin Freeman,1
Gavin Band,1 Suzannah J. Bumpstead,2 Sarah Edkins,2 Eleni Giannoulatou,1 Emma Gray,2
Serge Dronov,2 Sarah E. Hunt,2 Cordelia Langford,2 Richard D. Pearson,1 Zhan Su,1 Damjan Vukcevic,1
Alex W. Macharia,4 Sophie Uyoga,4 Carolyne Ndila,4 Neema Mturi,4 Patricia Njuguna,4
Shebe Mohammed,4 James A. Berkley,4 Isaiah Mwangi,4 Salim Mwarumba,4 Barnes S. Kitsao,4
Brett S. Lowe,4 Susan C. Morpeth,4,5,6 Iqbal Khandwalla,4 The Kilifi Bacteraemia Surveillance Group,
Jenefer M. Blackwell,7,8 Elvira Bramon,9 Matthew A. Brown,10 Juan P. Casas,11 Aiden Corvin,12
Audrey Duncanson,13 Janusz Jankowski,14 Hugh S. Markus,15 Christopher G. Mathew,16,17
Colin N.A. Palmer,18 Robert Plomin,19 Stephen J. Sawcer,20 Richard C. Trembath,21
Ananth C. Viswanathan,22 Nicholas W. Wood,23 Panos Deloukas,2 Leena Peltonen,2
Thomas N. Williams,4,5,24,25 J. Anthony G. Scott,4,5,6 Stephen J. Chapman,1,26 Peter Donnelly,1,27
Adrian V.S. Hill,1,28,30 and Chris C.A. Spencer1,27,30
Bacteremia (bacterial bloodstream infection) is a major cause of illness and death in sub-Saharan Africa but little is known about the role
of human genetics in susceptibility. We conducted a genome-wide association study of bacteremia susceptibility in more than 5,000
Kenyan children as part of the Wellcome Trust Case Control Consortium 2 (WTCCC2). Both the blood-culture-proven bacteremia
case subjects and healthy infants as controls were recruited from Kilifi, on the east coast of Kenya. Streptococcus pneumoniae is the
most common cause of bacteremia in Kilifi and was thus the focus of this study. We identified an association between polymorphisms
in a long intergenic non-coding RNA (lincRNA) gene (AC011288.2) and pneumococcal bacteremia and replicated the results in the same
population (p combined¼ 1.693 109; OR ¼ 2.47, 95% CI ¼ 1.84–3.31). The susceptibility allele is African specific, derived rather than
ancestral, and occurs at low frequency (2.7% in control subjects and 6.4% in case subjects). Our further studies showed AC011288.2
expression only in neutrophils, a cell type that is known to play a major role in pneumococcal clearance. Identification of this novel
association will further focus research on the role of lincRNAs in human infectious disease.
Introduction
Bacteremia is a common pathway in the progression to
death from severe pneumonia, meningitis, and sepsis,
which together account for an estimated 3 million deaths
each year globally in children under the age of 5 years.
Even in developed countries themortality rate from bacter-
emia remains unacceptably high.1–3 The leading bacterial
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cause of death in young children worldwide is Streptococcus
pneumoniae (pneumococcus), and 14.5 million episodes of
serious pneumococcal disease occur in young children
annually.4 A key question is why only a proportion of indi-
viduals develop invasive disease despite widespread expo-
sure and asymptomatic carriage of bacteria. Host genetic
factors play an important role in explaining inter-indi-
vidual variation in susceptibility to different infectious
diseases.5 However, the relevant genes for bacteremia sus-
ceptibility remain largely unknown.
To identify genetic correlates of bacteremia susceptibility,
we conducted a genome-wide association study (GWAS)
in Kenyan children, a population with a major disease
burden,6 as a part of the Wellcome Trust Case Control
Consortium 2 (WTCCC2). Bacteremia is a heterogeneous
phenotype and immune responses and genetic variants
affecting susceptibility are likely to be at least partially path-
ogen specific. We therefore focused on bacteremia caused
by S. pneumoniae, the most common bacteria found in our
study. In addition, all-cause bacteremia was analyzed in or-
der to assess the possible role of genetic risk factors for
bacteremia regardless of its etiology.
Subjects and Methods
Study Design
To identify host genetic determinants of susceptibility to invasive
pneumococcal disease in African children, we performed a two-
stage GWAS of pneumococcal bacteremia in 542 Kenyan children
with culture-confirmed disease and 4,013 healthy control sub-
jects. 429 case subjects and 2,677 control subjects were included
in the discovery phase analysis, with 113 case subjects and
1,336 control subjects included in the replication analysis. To
identify determinants of invasive bacterial disease irrespective of
the pathogen, we further performed a GWAS of culture-confirmed
all-cause bacteremia in the same population of Kenyan children
(discovery phase, 1,536 case subjects; replication phase, 434 case
subjects). Adopting a Bayesian framework, we considered evi-
dence for shared effects at loci associated with pneumococcal
disease and all-cause bacteremia, across pathogens commonly
causing bacteremia in this population. Finally, we character-
ized disease-associated genetic variation identified in the study,
analyzing tissue-specific expression of implicated transcripts in
immune cell subsets. A detailed study workflow is described in
Figure S1.
Study Participants
All study participants were residents of Kilifi District on the coast
of Kenya. Case subjects were recruited among children younger
than 13 years of age who were admitted to Kilifi District Hospital
(KDH) in Kenya between 1st August 1998 and 30th October 2010.
Blood cultures were investigated from everyone admitted (unless
they were admitted for elective procedures or because of minor ac-
cidents) using the BACTEC 9050 system. Children with bacteria
present in their bloodstream were defined as case subjects (Coryn-
eforms bacteria, Bacillus species, coagulase-negative Staphylococcus,
Staphylococcus saprophyticus, and Viridans group Streptococcus were
excluded as contaminants). The annual incidence of bacteremia in
Kilifi between August 1998 and July 2002 was estimated to be 505
cases per 100,000 children who were less than 5 years of age,6 but
the incidence has since decreased.7
Control subjects were selected from children born consecutively
within the same Kilifi region between 1st May 2006 and 30th April
2008 and represent the case subjects closely in terms of sex, ethnic
group, and geographic area of residence. Although the control in-
dividuals are part of a birth cohort study and thus aged less than
12 months at the time of recruitment to the study, we have been
able to review their follow-up data in terms of development of
bacteremia (n ¼ 12), mortality (n ¼ 49), etc. (See further demo-
graphic details of case and control subjects in Table S2.) Table S3
shows the distribution of the most common bacterial isolates
identified from bacteremia case subjects in the discovery and
replication sets. The final discovery set included 1,536 blood-cul-
ture-proven bacteremia case subjects (of whom 429 were pneumo-
coccal) and 2,677 healthy infants as control subjects. Individuals
in the replication set were enrolled during the end of the collec-
tion period and included 434 bacteremia case subjects (of whom
113 were pneumococcal) and 1,336 control subjects.
Ethical approval was granted by the Kenya Medical Research
Institute (KEMRI) National Scientific Steering and Research Com-
mittees and the Oxford Tropical Research Ethics Committee
(OXTREC). Informed consent was obtained from all subjects.
DNA Sample Preparation
Genomic DNA was extracted at the Kenya Medical Research Insti-
tute (KEMRI)-Wellcome Trust Collaborative Programme in Kenya,
using the QIAamp DNA blood mini kit (QIAGEN) and shipped to
the Wellcome Trust Centre for Human Genetics, University of
Oxford, for further processing. Genomic DNA was whole-genome
amplified at the GeneService laboratory with GenomiPhi (GE
HealthCare) scaled to amplify 40–50 mg of DNA. Quality of the
whole-genome amplified DNA was assessed at the Wellcome Trust
Sanger Institute as described elsewhere8 before genotyping.
Genome-wide Genotyping and Quality Control
Whole-genome amplified samples from case and control subjects
were genotyped on the genome-wide Affymetrix SNP 6.0 chip at
the Affymetrix service laboratory. Genotypes were called with a
modified version of the Chiamo software9 for all samples passing
the Affymetrix laboratory quality control measures. Sample QC
was performed as described elsewhere8 and details are provided
in Table S1 and Figures S1–S3. Analysis of pairwise allele sharing
identified 68 duplicate pairs and 6 triplicates (Figure S4). Pheno-
typic information suggests that the majority of these duplicate
and triplicate individuals were unintentionally recruited to the
study in Kenyamore than once rather than being sample handling
problems; therefore, one of each of the duplicate pairs or tripli-
cates was included in the analysis (a case rather than a control
subject was included in the analysis; otherwise the sample
with a higher call rate was included). First-degree relatives
(genome-wide IBD sharing probability > 0.4; 117 individuals)
were removed from the main analysis. The following criteria
were used to exclude 102,896 unreliable SNPs: minor allele fre-
quency (MAF) < 1% (50,322 SNPs), info < 0.975 (53,419 SNPs),
Hardy-Weinberg equilibrium p < 1 3 1020 (18,288 SNPs), plate
effect p < 1 3 106 (7,382 SNPs), and SNP missingness > 2%
(34,430 SNPs). Genotyping cluster plots of each SNP with
p < 1 3 103 were visually inspected using Evoker,10 and SNPs
with poor cluster separation were removed. After sample and
SNP QC, 1,536 case subjects and 2,677 control subjects were
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analyzed at 787,861 genotyped autosomal SNPs. Three main eth-
nicities—namely Chonyi, Giriama, and Kauma—were discernible
with principal-components analysis (PCA) of the genome-wide
data (Figure S5).
Immunochip Genotyping
Approximately 2,000 SNPs out of the total 200,000 SNPs were
selected to be included in the ImmunoChip array11 based on the
initial association results of the bacteremia analyses. The replica-
tion set was genotyped with this array at the Wellcome Trust
Sanger Institute. All the samples went through a similar QC pro-
cess as described above for the discovery samples (Table S1) and
434 case subjects and 1,336 control subjects passed the QC. After
excluding SNPs based on minor allele frequency < 1%, SNP call
rate < 95% (<99% if MAF < 5%), and Hardy-Weinberg equilib-
rium p < 1 3 1010, 143,100 SNPs remained for the further
analyses. The same ethnicities were detectable by PCA in the repli-
cation sample set as in the discovery analysis (Figure S6). As the
ImmunoChip genotyping was performed before the imputation,
these genotypes were mainly utilized to account for population
stratification and relatedness in the later replication analyses.
Imputation and Association Analyses
We performed whole-genome imputation using the 1000 Ge-
nomes Phase I data as a reference panel. Genotypes were
pre-phased using SHAPEIT12 before imputation with IMPUTE2.13
Only samples and SNPs passing the QC were included for pre-
phasing and imputation. SNPs with potentially unreliable impu-
tation were filtered out based on MAF (<2%), imputation info
value (<0.8), and Hardy-Weinberg equilibrium (p < 1 3 1010).
10,996,499 imputed autosomal SNPs that passed the QC were
analyzed for additive and genotypic models using SNPTEST2,14
taking the imputed genotype uncertainty (frequentist score test)
and the first two principal components (PCs) of genetic structure
into account. The genomic control parameter l for bacter-
emia overall and pneumococcal bacteremia after imputation and
QC were 1.043 and 1.013, respectively (see the QQ plots in
Figure S7). At associated SNPs, statistical tests were also performed
using a linear mixed model that uses genome-wide data to model
the pair-wise relatedness among the individuals.15
Sequenom Replication and Confirmation of
Imputation Accuracy
SNPs with p < 1 3 105 in the additive model or p < 5 3 107 in
the genotypic model were directly genotyped in the discovery set
to confirm imputation accuracy and in the replication sample set
to confirm the associations using two Sequenom iPLEX assays.
Five SNPs looked unreliable after inspection of the cluster plots,
leaving 37 SNPs in the analysis (the cluster plot for themost signif-
icant SNP is shown in Figure S8). All of these SNPs had a call rate
greater than 95% and the genotype distribution among controls
obeyed Hardy-Weinberg equilibrium (p > 0.05). After removing
the samples that were originally excluded from the discovery
and Immunochip analyses, 102 and 80 samples were removed
because of the low call rate (<80%) and 7 and 9 samples because
of the mismatching gender from the first and second multiplexes,
respectively. This left 1,514 case subjects (418 pneumococcal
cases) and 2,642 control subjects in the discovery sample set and
407 case subjects (103 pneumococcal cases) and 1,333 control sub-
jects in the replication analyses. Genotyping of these two iPlexes
was performed at the Wellcome Trust Sanger Institute. The func-
tional SNP rs334 in HBB failed the initial assay design, and was
therefore genotyped separately using a Sequenom iPlex at the
Wellcome Trust Centre for HumanGenetics, University of Oxford.
The QC measures described above were applied to these samples,
leaving 1,360 case subjects and 2,644 control subjects in the
discovery set and 389 case subjects and 1,312 control subjects in
the replication set.
Only the samples that were included in either the discovery set
or ImmunoChip replication set were included in the final analysis
to allow inclusion of the first two PCs in logistic regression analysis
using PLINK16 and to model the pair-wise relatedness in a linear
mixed model. The combined statistics for the discovery and repli-
cation samples were obtained using fixed effects meta-analysis in
GWAMA.17 The replication dataset had 80% power to detect an as-
sociation (p < 0.05) with a common SNP (MAF 0.20) that has an
effect size R 1.3, but for more rare SNPs (MAF ¼ 0.05), an effect
size R 1.54 was required (see Figure S9). Therefore, we did not
have sufficient statistical power to reliably replicate associations
with modest effect sizes.
Approaches to Handle Relatedness
The SNPs chosen for replication were also analyzed via a linear
mixed model15 that uses genome-wide data to model the pair-
wise relatedness among the individuals, and which also included
the first two PCs as covariates, to better account for relatedness
and possible population structure within the sampled individuals.
This was done by including all relatives and also by including only
distantly related individuals (r < 0.2).
We further assessed whether the sample set with pneumococcal
infection includes more pairs of close relatives than other bacter-
emia case subjects or than control subjects. This was assessed
by comparing the observed number of relative pairs with esti-
mated r > 0.025 among the pneumococcus case subjects to an
equal-sized set of the rest of the case or control subjects that are
matched with respect to manual clustering (Figure S11) by resam-
pling 100,000 datasets.
Bayesian Model Comparisons
To compare models of the similarity of effect across bacterial
species at identified disease-associated loci, we took a Bayesian
approach (for a similar approach, see Band et al.18 and Bellenguez
et al.19). The likelihood function is based on multinomial regres-
sion with strata corresponding to the control subjects and each
of the seven most common bacterial subgroups (Figure 2; Table
S3). Case subjects infected with more than one of these seven
different bacterial species (2.1% of case subjects) are included in
the analysis for each group.
Theparameters of interest are the genetic effect sizes (bk, k¼1,..,7)
on a log-odds scale for each of the case cohorts. We first find
maximum likelihood estimates (with the corresponding observed
information matrix) by including two PCs as covariates in the
model, and then compute approximate Bayes factors using amulti-
variate normal approximation to the likelihood and the prior. The
models are defined by prior distributions on the parameters bk:
NULL: bk¼ 0 for all k ¼ 1,..,7, i.e., no effects, all case groups are
like the control group.
SAME: bk ~N(0,1) and cor(bi,bj) ¼ 1 for all pairs is j, i.e., each
bk is the same.
REL: bk ~N(0,1) and cor(bi,bj) ¼ 0.96 for all pairs i s j, i.e.,
bi and bj are correlated but not necessarily the same.
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Additional models are defined after inspection of the observed
association at each locus for each pathogen. Bacterial species hy-
pothesized to be associated with a given locus are assumed to
have the same non-zero effect with a prior of N(0,1), whereas for
other pathogens the effect is 0.
Quantification of lincRNA Expression in Primary
Immune Cell Subsets
Previous reports suggest that AC011288.2 encodes a lincRNA and
is expressed in white blood cells and placental tissue. To identify
which leukocyte population this lincRNA is expressed in, we
isolated monocytes, B cells, and natural killer (NK) cells from
consenting healthy adult European-ancestry donors using mag-
netic activated cell sorting (MACS, Miltenyi), as previously
described.20 In addition, we isolated granulocytes (predominantly
neutrophils) using Polymorphoprep (Allere) according to the
manufacturer’s instructions from eight individuals. The purity of
cell subsets after cell separation was assessed by flow cytometry
and was >90% in a representative sample. Viability after sorting
was assessed by the Trypan Blue dye exclusion method and
observed to be >95% in all cases. Total RNA was extracted with
the RNeasy mini kit (QIAGEN) or TRIzol (Life Technologies)
according to the manufacturer’s instruction (QIAGEN). Total
RNA was quantified by Nanodrop and Bioanalyzer for a subset ac-
cording to the manufacturers’ instruction (Bioanalyzer RNA 6000
Nano kit, Agilent).
To quantify levels of lincRNA expression, we performed quan-
titative real-time PCR (qPCR) using a relative quantification
method. Beta-Actin (ACTB) was selected as a reference gene based
on previous reports of its stable expression in neutrophils. Single-
strand complementary DNA was synthesized by reverse transcrip-
tion with the SuperScriptIII First-Strand Synthesis System (Invitro-
gen). Primers specific to each of the two reported transcripts for
the lincRNA AC011288.2 gene were designed: AC011288.2-001
(for, 50-GTCAGAAGCGGGGTTCAAAG-30; rev, 50-TTTAATTCT
TGAGTTCTGCAGGC-30) and AC011288.2-002 (for, 50-GATGC
TAAGCCTGGAAACCC-30; rev, 50-TCCAGCTTCTATTCCCAGA
GG-30). In addition we designed primers to AC006000.5 (for,
50-ACTCCACGTCCCACAGATAC-30; rev, 50-TGACAGAGTGAGAC
CCTGTG-30) but consistent with previous reports that observed
no expression in leucocytes, we did not identify any individuals
that expressed this transcript and do not describe it further. To
avoid potential amplification of genomic DNA, primers were de-
signed to span exons. qPCR was performed using SYBR Green
Supermix (BioRad) on a CFX96 Real-Time PCR Detection System
(Bio-Rad). Reactions were run in duplicate with 1 cycle at 95C
(10 min), followed by 42 cycles consisting of denaturation at
95C (10 s), annealing at 58C (20 s), and extension at 72C
(20 s). Detection of the fluorescent products was carried out at
the end of the 72C extension period. To confirm amplification
specificity, the PCR products were subjected to a melting curve
analysis and agarose gel electrophoresis. Detection of a fluorescent
product after cycle 38 (Ct¼ 38) was considered evidence of expres-
sion beneath the confident detection limit based on careful in-
spection of the melting curves and agarose gel electrophoresis
results. Therefore, if Ct values of greater than 38 were obtained,
the Ct value was re-assigned to 38, so as to conservatively estimate
the highest level of expression beneath the detectable level. On
average, the Ct value for AC0011288.2-001 was 33 cycles in neu-
trophils. Relative gene transcript levels were determined by the
[DELTA][C.sub.T] method expressed relative to ACTB. Compari-
sons of log10 transformed relative expression levels were made us-
ing a non-parametric Mann-Whitney test in GraphPad Prism.
Results
Genome-wide Association Results of Directly
Genotyped Discovery and Immunochip Replication
Sets
We identified several suggestive associations in the directly
genotyped discovery data both in pneumococcal bacter-
emia and bacteremia overall analyses in Kenyan children
(Table S4), but none of the SNPs reached established
criteria for identifying novel associations (p < 5 3 108)
in a combined analysis after replication.
Genome-wide Association Results of Bacteremia
Caused by Streptococcus pneumoniae after Imputation
and Replication
After genome-wide imputation and quality control, nearly
10 million autosomal SNPs were included in the associa-
tion analyses of pneumococcal bacteremia (Figure S10).
In this analysis of 429 case and 2,677 control subjects, 17
SNPs in a single region on chromosome 7 were associated
with disease at a level exceeding genome-wide significance
(p < 5 3 108), with the peak of that association observed
at rs140817150 (p imputed¼ 7.253 109; OR¼ 2.74) (Fig-
ures S10 and 1). This novel associated region includes two
overlapping long intergenic non-coding RNA (lincRNA)
genes: AC00600.5 and AC011288.2. The association at
rs140817150 was confirmed by direct genotyping (p dis-
covery ¼ 3.58 3 107; OR ¼ 2.39) and replication (p ¼
1.16 3 103; OR ¼ 2.72), resulting in a combined OR esti-
mate of 2.47 (95%CI 1.84–3.31) and p value of 1.693 109
(see Table S5 for a list of all suggestive associations in the
analysis of pneumococcal bacteremia and Table S6 for
the comprehensive list of associated SNPs in the chromo-
some 7 top associated region). Direct genotyping of the
top imputed SNPs confirmed that imputation was gener-
ally accurate (average concordance between imputed and
directly genotyped genotypes was 98.3%). In order to pro-
tect against spurious associations due to possible cryptic
relatedness, the SNPs chosen for replication were also
analyzed using the mixed model approach (rs140817150;
p combined ¼ 1.5 3 1010, OR ¼ 2.66; Table S7) and by
stratifying individuals on the basis of genetic background
across themain ethnic groups (rs140817150; p discovery¼
1.53 107, OR¼ 2.54; Figure S11). By either approach, the
evidence for association remained strong. The pneumo-
coccal case subjects do not have more close relatives than
the control subjects in any of the four ancestry groups
(p R 0.22). When compared to other case subjects, they
show elevated levels of relatedness (p < 0.05) in group
1 only, which does not contribute strongly to the observed
association signal (Figure S11). After conditioning on the
top SNP, no associations were detected with p < 104 in
the region.
The American Journal of Human Genetics 98, 1092–1100, June 2, 2016 1095
Genome-wide Association Results of Bacteremia
Overall after Imputation and Replication
In addition to the analysis of a more homogeneous pheno-
type, pneumococcal bacteremia, all-cause bacteremia over-
all (Figure S12) was also analyzed. Table S8 summarizes loci
with the strongest evidence of association in bacteremia
overall after imputation, including the replication results.
The only genome-wide significant (p < 5 3 108) associa-
tion signal that replicated was under the genotypic model,
which allows independent effects on risk for homozygotes
and heterozygotes. It revealed a strong association at the
previously identified HBB locus (rs113892119, p ¼ 5.08 3
1013). The region of association included the functional
rs334 polymorphism (p ¼ 1.33 3 1010) that leads to the
production of hemoglobin S (HbS)21 and is located 25.6
kb upstream from the most associating SNP rs113892119.
As previously described, rs334 was associated with
susceptibility among homozygotes22 (HbSS versus HbAA;
directly genotyped combined p ¼ 2.66 3 1012, OR ¼
4.9) and with protection from bacteremia among heterozy-
gotes7 (HbAS versus HbAA; directly genotyped combined
p ¼ 4.67 3 103, OR ¼ 0.77). These same effects are seen
in the most common bacterial subgroups (Figure S13).
Bayesian Model Comparison Results of rs140817150
and rs334 Associations with Common Causes of
Bacteremia in Kenyan Children
Although the associationwith rs140817150was discovered
in the pneumococcal bacteremia analysis, we were able to
utilize the all-cause bacteremia data at this locus to assess
its effect on susceptibility to bacteremia caused by other
species (Figure 2). To assess whether the data were consis-
tentwith the same effect among case subjectswith different
species of bacteremic pathogen, we compared models
via a Bayesian approach (Figure 2). Assuming all models
to be equally likely a priori, the most probable model is
the one in which the susceptibility is confined to pneumo-
coccus, Acinetobacter species, and Haemophilus influenzae.
Removing thepneumococcal group, fromwhich the associ-
ationwas ascertained,weakened the evidence for effect het-
erogeneity. The same effect in all subtypes was found to be
the most probable model for rs334 association (heterozy-
gote risk and homozygote protection) in HBB (Figure S13).
lincRNA Expression in Primary Immune Cell Subsets
We assessed AC011288.2 RNA expression in the major
leukocyte cell subsets and observed expression only in neu-
trophils. Expression levels were below the detection limit
inmonocytes, B cells, andnatural killer (NK) cells (Figure 3).
To verify that expression of this transcript is constitutive in
neutrophils, we measured expression in an additional 75
donors, recruited in a separate study,23 and observed detect-
able expression in all 75 donors. We did not observe
AC00600.5 expression in any leukocyte subsets.
Discussion
We report here a GWAS of bacteremia susceptibility, which
is one of the few large-scale GWASs conducted in an
Figure 1. Signal of Association around rs140817150 in the Discovery Analysis of Pneumococcal Bacteremia
Imputed SNPs are shown as circles and directly genotyped SNPs as triangles with colors indicating the correlation (r2 in 1000 Genomes
data) with rs140817150. A set of SNPs that contains the causal SNP with greater than 95% probability is ringed with circles. Annotated
genes (blue) and lincRNAs (red) are shown in the bottom panel along with the fine-scale recombination rate.
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African population to date. We identified an association
between polymorphisms in two overlapping long inter-
genic non-coding RNA (lincRNA) genes (AC00600.5 and
AC011288.2) and pneumococcal bacteremia, the most
common cause of bacteremia in our study set. Although
immune responses and genetic variants affecting bacter-
emia susceptibility are likely to be at least partially path-
ogen specific, we also analyzed the bacteremia overall
dataset to identify more universal risk factors. The only
genome-wide significant hit for bacteremia overall was in
a previously reported gene,HBB, including the well-known
rs334 polymorphism associated with the production of
sickle hemoglobin.21
The lincRNA risk allele at rs140817150 is derived (as
reported on dbSNP) rather than ancestral, its frequency is
low (2.7% in control subjects, 6.4% in pneumococcal
bacteremia case subjects), and according to the 1000
Genomes project data (phase 3), it is polymorphic only
in African populations. Consistent with the local recombi-
nation landscape and with the expectation that low-fre-
quency derived alleles are relatively young, SNPs in linkage
disequilibrium with rs140817150 extend over 500 kb
(Figure 1). However, Bayesian analysis of the region of asso-
ciation24 in the imputed data suggests there is greater than
95% probability that one of the most associated SNPs
(circled in Figure 1) is the causal variant, assuming there
is a single causal variant, and it is imputed accurately in
our dataset.
The association peak is located in the introns of two
separate long intergenic non-coding RNAs (lincRNAs), an-
notated as AC011288.2 and AC006000.5. The importance
of lincRNAs as key regulators of gene expression has only
recently been recognized.25–27 It has been estimated that
the human genome includes at least 10,000 lincRNAs
but only a fraction of these has a known function.25–27
A recent study aiming to catalog the function of more
than 8,000 human lincRNAs reported that lincRNA expres-
sion is significantly more tissue specific than expression of
protein-coding genes.28 AC006000.5 is listed in the catalog
but it is not expressed in any of the studied tissues, whereas
AC011288.2 is reported to be expressed only in placenta
and white blood cells out of 24 different tissues and cell
lines studied. We assessed AC011288.2 RNA expression
in leukocyte cell subsets and observed expression only
in neutrophils, a cell type that is known to play a major
role in pneumococcal clearance.29,30 These results provide
an important direction for future functional investiga-
tions. Neutrophils express many antimicrobial peptides
and proteins that confer both universal and pathogen-
specific host response,31,32 and it has been shown that
absolute neutrophil count is an independent predictor of
pneumococcal bacteremia in febrile children.33
The closest protein-coding genes surrounding the associ-
ation signal are ARL4A and ETV1 but there is no evidence
that the associating lincRNAs regulate these two genes.
However, data from a previous expression quantitative trait
locus (eQTL) study20 suggest that there are someSNPs in the
associating region that function as eQTLs in monocytes
(rs1432496) and B cells (rs2568633) for PHF14 (PHD finger
protein 14), a transcription factor that downregulates
PDGFRa expression.34 However, neither is correlated with
our most-associated SNP (r2 < 0.01 in 1000 Genomes
data). Although the role of lincRNAs in human infections
is unknown, recent mouse studies have indicated that
some lincRNAs can act in immune cells to regulate host
susceptibility to bacterial and viral infections.35,36
Using the GWAS approach, we have identified an asso-
ciation between a genetic variation in a lincRNA gene
and pneumococcal bacteremia. Furthermore, we have
confirmed a previously reported association between HBB
and bacteremia overall,22 with homozygotes associated
with strong susceptibility but heterozygotes associated
Figure 2. rs140817150 lincRNA Associa-
tion with the Main Bacterial Infections
(A) Log transformed combined odds ratios
and 95% confidence intervals of directly
genotyped discovery and replication sam-
ples. The dotted line represents the log
OR of 0 (OR of 1; no difference between
case and control subjects). The values of
point estimates and standard errors (in
parentheses) are also given. Bacterial infec-
tion abbreviations are as follows: PNEUM,
Streptococcus pneumoniae (pneumococcus);
ACINET, Acinetobacter species; HAEMOPH,
Haemophilus influenzae; ECOLI, Escherichia
coli; SALMON, Salmonella (non-typhoi-
dal); STREPBH, Streptococcus beta hemolytic;
SAUR, Staphylococcus aureus.
(B)Theposteriorprobabilitiesonthemodels
of association: no effect in any subtype
(NULL), same effect in all subtypes (SAME),
related effects across subtypes (REL), or the same non-zero effect only in PNEUM, ACINET, and HAEMOPH (PþAþH), in PNEUM and
ACINET (PþA), or in PNEUM(P). (See Subjects andMethods.)Models are a priori assumed to be equally likely. Bayes factors,which compare
the evidence (marginal likelihood) between any pair of models, can be calculated as the ratio of the posterior probability assigned to each
model as reported under each bar of the plot.
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with protection. At both associated loci, the disease-associ-
ated alleles are rare in individuals without African ancestry
(monomorphic in1000GenomesProject data inother than
African populations) and exert a large effect on the likeli-
hood of developing bacteremia. These associations have
not been reported by earlier GWASs of related phenotypes,
which is unsurprising because the populations under study
have been of European decent and differences in pheno-
types are still substantial.37,38 The reported SNPs in FER
(MIM: 176942) that was recently associated with outcome
from sepsis due to pneumonia37 or in CFH (MIM: 134370)
and CFHR3 (MIM: 605336) that have been associated with
meningococcal disease38didnot showanyevidenceof asso-
ciation in the current study (p > 0.05). Given the likely
importance of host-pathogen molecular interactions in
bacteremia susceptibility, it is plausible that the effect of a
risk allele will be dependent on bacterial species. Our data
on the lincRNA locus provide initial evidence for this at
the bacterial species level, and motivate approaches that
stratify host genetic associations by pathogen species,
serotype, or genotype. Understanding themolecularmech-
anisms leading to the doubled risk of pneumococcal bacter-
emia associated with this allele could provide new clues in
the pressing search for new therapeutic targets.
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Genotype data will be made available by the WTCCC access
process, via the European Genotype Archive under the accession
number EGAS00001001756.
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 Supplemental Figures 
Figure S1: Bacteremia GWAS workflow 
Genomic DNA whole-genome amplified with GenomiPhi kit 
Discovery GWAS: ~2000 cases and ~3000 controls submitted to Affymetrix for genotyping after 
passing the sample QC performed at Sanger 
- Number of excluded samples based on QC: 581 
o Failed at Affymetrix: 92 
o Call rate/heterozygosity: 182 (Figure S2) 
o Discrepancy between Sequenom and Affymetrix genotyping: 17 (5 that otherwise passed the QC) 
o Channel: 14 
o Gender discrepancy or unknown reported gender: 110 (32 that otherwise passed the QC) 
o Population outlier (PCA): 186 (Figure S3) 
o Duplicate individuals:  103 (of which 16 are intentional for QC purposes) 
o Relatedness (Siblings removed but more distant relatives kept in the analysis, pi_hat>0.4): 117 
- Exclusion based on phenotype: 130 (See Table S1 for further details) 
- Analysis of 1536 cases and 2677 controls using the first two principal components as covariates (PLINK) 
- 2000 SNPs selected for Immunochip replication: 
o 1000: SNPs chosen based on bacteremia overall analysis 
o 1000: SNPs chosen based on different species of bacteremic pathogen 
 
Immunochip replication: ~500 cases and ~1500 controls 
- Number of excluded samples based on QC:212  
o Call rate/heterozygosity: 84 
o Discrepancy between Sequenom and ImmunoChip genotyping: 8 
o Channel: 4 
o Gender discrepancy: 5 (0 that would have otherwise passed the QC) 
o Population outlier (PCA): 51 
o Duplicate individual: 6 
o Duplicate individual between GWAS and Immunochip: 29 
o Relatedness (Siblings removed but more distant relatives kept in the analysis, pi_hat>0.4): 29 
- Exclusion based on phenotype: 37 (See Table S1 for further details) 
- Analysis of 434 cases and 1336 controls using the first two principal components as covariates (PLINK) 
- No Genome-wide significant hits with bacteremia overall or in bacterial subgroups in the combined analysis 
 
Imputation of the discovery set using individuals in the 1000 Genomes Project as a reference panel: 
- Phasing with SHAPEIT (QCd set of samples and SNPs) 
- Imputation with IMPUTE2 
- Association analysis with SNPTEST2 using the score method and additive and genotypic models of 
association 
o SNPs with Info<0.8 and MAF<0.01 excluded 
- The most promising associations selected for direct genotyping with Sequenom 
 
 
 Direct Sequenom genotyping of the discovery and replication samples: 37 SNPs in 3 iPLEX assays 
- Samples excluded based on a call rate of <80% and mismatching gender 
- Discovery and replication samples analyzed separately 
o Discovery: 1514 cases and 2642 controls that passed the GWAS QC earlier 
o Discovery of rs334 (HBB): 1360 cases and 2644 controls 
o Replication: 407 cases and 1333 controls that earlier passed the ImmunoChip QC 
o Replication of rs334 (HBB): 389 cases and 1312 controls that passed the ImmunoChip QC 
o Two loci reached genome-wide significance: HBB in bacteremia overall (genotypic model) and a 
lincRNA in the pneumococcal subgroup (allelic model) 
 
- Mixed Model analysis to better account for relatedness and underlying population structure 
o Siblings and more distantly related individuals included in the analysis: 
 Discovery: 1519 cases and 2688 controls 
 Replication: 408 cases and 1360 controls 
o All related individuals (r>0.2) excluded from the analysis: 
 Discovery: 1476 cases and 2543 controls 
 Replication: 404 cases and 1311 controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure S2. Sample exclusions based on call rate (x-axis) and heterozygosity (y-axis). Excluded samples 
are shown in red. 
 
 
 
 
 
 
 
 
 
 
 Figure S3. Principal components analysis for bacteremia cases and controls (A) analyzed together 
with HapMap individuals and (B) zoomed into the bacteremia cluster to show the population outlier 
exclusions (red). BS = bacteremia susceptibility; CEU = Utah residents with Northern and Western 
European ancestry from the CEPH collection; JPT = Japanese in Tokyo, Japan; CHB = Han Chinese in 
Beijing, China; YRI = Yoruba in Ibadan, Nigeria.    
A)  
 
B) 
 
 Figure S4. Relatedness shown by estimated identity by descent (IBD) across the genome for the 4000 
most related sample pairs. Each vertical line represents a pairwise comparison of two individuals: 
red indicates two alleles IBD, blue indicates one allele IBD, and grey indicates zero alleles IBD. 
Thereby duplicate samples (or monozygotic twins) are shown with a full red line. Sibling pairs result 
in lines that are approximately one quarter red, half blue, and one quarter grey. Partly grey and 
partly blue lines represent sample pairs that are less related, i.e. cousins, second cousins etc. The 
dotted horizontal lines indicate 25% centiles.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure S5. The first and second axes of the principal components analysis in the discovery dataset 
using 168,217 SNPs. Color coding represents A) reported ethnicity and B) case control status. 
A)
 
B)
 
 
 
 Figure S6. The first and second axes of the principal components analysis in the ImmunoChip 
replication dataset using 27,026 SNPs. Color coding represents A) reported ethnicity, B) case control 
status. 
A)
 
B)
 
 
 
 Figure S7. QQ-plots of the pneumococcal bacteremia (=1.013) and bacteremia overall (=1.043) 
analyses after imputation and data cleaning. Association analyses were performed with SNPTEST2 
(additive model). After the SNPTEST analysis, every SNP with a minor allele frequency < 0.02, info < 
0.8, or Hardy-Weinberg equilibrium P < 1x10-10 were excluded.  
 
 Figure S8. Sequenom cluster plot for the rs140817150 SNP (chr7 lincRNA, pneumococcal 
bacteremia). 
 
Figure S9. Statistical power to detect an association with a p-value of 0.05 in the replication data set 
(434 cases and 1336 controls) with varying odds ratio and minor allele frequency (MAF) as indicated. 
 
 Figure S10. Manhattan plot for the pneumococcal bacteremia discovery analysis (additive model) 
after imputation. SNPs with minor allele frequency > 2% and info value > 0.9 are included (9,337,574 
SNPs). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure S11. rs140817150 lincRNA and rs334 HBB associations with pneumococcal  bacteremia and 
bacteremia overall, respectively, in the discovery data set stratified by the main ethnic groups.  
A) Left panel: The three largest ethnic groups with the first two principal components of genetic 
structure. Right panel: Manual clustering of the individuals into four groups reflecting reported 
ethnicities. Sizes of groups are in the legend.  
B) Log odds-ratios separately for the four groups defined in the right panel of (A), and their 
combined estimate.  
A)
 
B) 
 
  
 
 
 
 
 
 
 
 Figure S12. Manhattan plots for the bacteremia overall discovery analysis after imputation in the 
additive (A) and the genotypic (B) models.  SNPs with minor allele frequency of > 2% and a model 
specific info value > 0.8 are included (10,996,498 and 8,156,976 SNPs in the additive and genotypic 
models respectively). 
A) 
 
B)
 
 Figure S13. HBB association (rs334) with the main bacterial infections. Left panel: Log transformed combined odds ratios 
and 95% confidence intervals of directly genotyped discovery and replication samples. The dotted line represents the 
log OR of 0 (OR of 1; no difference between cases and controls). The values of point estimates and standard errors (in 
parentheses) are also given. Bacterial infections: PNEUM=Streptococcus pneumoniae (pneumococcus); 
ACINET=Acinetobacter species; HAEMOPH= Haemophilus influenzae; ECOLI=Escherichia coli; SALMON= Salmonella (non-
typhoidal); STREPBH=Streptococcus beta hemolytic; SAUR=Staphylococcus aureus. Right panel: The posterior 
probabilities on the models of association: no effect in any subtype (NULL), same effect in all subtypes (SAME), related 
effects across subtypes (REL) or a same non-zero effect only in ECOLI (E) (See Methods). Models are a priori assumed to 
be equally likely. Bayes factors, which compare the evidence (marginal likelihood) between any pair of models, can be 
calculated as the ratio of the posterior probability assigned to each model as reported under each bar of the plot. 
 
 
 
 Supplemental Tables 
Table S1. Sample exclusions in the discovery data and ImmunoChip replication sets. 
Exclusion criteria Number of excluded discovery 
samples 
Number of excluded 
ImmunoChip 
replication samples 
Call rate and extreme heterozygosity 182 84 
HapMap PCA outliers 186 51 
Outlying channel intensity 14 4 
Sequenom disconcordance (N that otherwise 
passed the QC) 
17 (5) 8 (7) 
Discrepant or undetermined gender (N that 
otherwise passed the QC) 
110 (32) 5 (0) 
Intentional duplicate samples for QC purposes 16 0 
Duplicate samples 87 6 
Relatedness (r>0.4)  117 29 
Duplicates when compared with discovery samples NA 29 
Exclusions based on phenotype (altogether): 130 37 
               Missing clinical data        3        0 
               Contaminant, not bacteremia        9        0 
               Fungemia, not bacteremia        4        0 
               Meningitis, not bacteremia        44        0 
               Not bacteremia        25        1 
               Pneumonia, empyema, not bacteremia        15        0 
               Uncertain pathogen        30        1 
               Malaria, not bacteremia        0        35 
Samples after QC 4213 1770 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table S2. Demographic data for cases and controls in discovery and replication sets.  
 Cases 
(discovery; 
N=1536) 
Cases 
(replication; 
N=434) 
Controls 
(discovery; 
N=2677) 
Controls 
(replication; 
N=1336) 
Mean age in years (range)* 2.3 (0-13) 2.1 (0-13) 5.1 (0-6.9) 4.9 (0-6.7) 
Proportion of individuals aged <2 months 16.5 % 26.5 % 0.19% 0.2% 
Proportion of individuals aged 2 months – 2 
years 
47.4 % 39.7 % 5.0% 6.4% 
Proportion of individuals aged 2 – 5 years 21.2 % 22.5 % 23.8% 43.8% 
Proportion of individuals more than 5 years 14.8 % 11.4 % 70.7% 49.3% 
Missing age information 0 0 0.3% 0.3% 
Bacteremia 100% 100% 0.3% 0.2% 
Mortality 25.8 % 26.1 % 0.9% 1.9% 
Females 42.7 % 47.0 % 49.6 % 49.5 % 
Reported ethnicity: Giriama 57.8 % 54.3 % 45.8 % 40.0 % 
Reported ethnicity: Chonyi 24.9 % 25.0 % 37.1 % 44.1 % 
Reported ethnicity: Kauma 7.3 % 12.5 % 11.9 % 10.3 % 
*Controls belong to a birth cohort, hence all these children were less than 12 months of age when recruited to the 
study. The age of controls listed in this table refers to the age at the latest follow-up date.    
 
 
Table S3. Distribution of the most common bacterial species in the discovery (1536 cases) and replication sets (434 
cases). 
Bacterial species Discovery samples Replication samples 
Streptococcus pneumoniae 429 (27.9%) 113 (26.0%) 
Salmonella (non-Typhi) 180 (11.7%) 38 (8.8%) 
Staphylococcus aureus 178 (11.6%) 46 (10.6%) 
Escherichia coli 162 (10.6%) 43 (9.9%) 
Streptococcus beta-hemolytic 160 (10.4%) 48 (11.1%) 
Haemophilus influenzae 134 (8.7%) 31 (7.1%) 
Acinetobacter species 130 (8.5%) 48 (11.1%) 
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Table S4. Association results of the bacteremia overall and pneumococcal bacteramia analyses (additive test) after direct genotyping. GWAS discovery analysis (logistic regression 
using the first two principal components as covariates in PLINK) included 1536 cases with microbiologically proven bacteremia (429 pneumococcal) and 2677 controls. 
Approximately 2000 SNPs were included in the ImmunoChip replication (approximately P < 1x10-3), which were genotyped in 434 cases (113 pneumococcal) and 1336 controls. All 
of the SNPs with P < 1x10-5 in the discovery analyses are included in the table. In addition, SNPs with P <10-3 are shown, if they replicated in the same direction with P < 0.05. SNPs 
highlighted in bold show suggestive association and replication in the same direction, although none of these reached the genome-wide significance level of P < 5x10-8. OR = odds 
ratio; “Effects” shows the direction of association in the discovery and replication sets (“+” = minor allele confers a risk; “-“ = minor allele is protective).  
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1 rs6669008 114166561 overall 0.000884 1.27 0.00078 1.48 4.71E-06 1.32 ++ MAGI3 
2 rs207413 31539280 overall 1.32E-06 1.58 0.9735 0.99 1.76E-05 1.44 +-  
2 rs6716368 139924118 overall 0.000127 1.26 0.02504 1.27 9.24E-06 1.26 ++  
3 rs10510428 14617925 overall 0.000253 1.18 0.02187 1.2 1.57E-05 1.19 ++  
3 rs3922843 38624343 overall 0.000113 0.81 0.04668 0.83 1.47E-05 0.82 -- SCN5A 
3 rs9869826 50998816 overall 2.88E-08 0.71 0.7553 1.03 4.43E-06 0.79 -+ DOCK3 
3 rs7633054 62138954 overall 8.23E-07 1.39 0.04803 1.27 1.45E-07 1.36 ++ PTPRG 
3 rs9853409 62157762 overall 3.67E-06 1.34 0.3831 1.10 8.40E-06 1.28 ++ PTPRG 
4 rs4694744 70326656 overall 2.98E-05 0.65 0.00635 0.57 7.22E-07 0.63 --  
4 rs1080755 70344641 overall 0.000203 0.68 0.0265 0.65 1.57E-05 0.68 -- UGT2B4 
4 rs13116232 70358525 overall 0.000219 0.68 0.0145 0.60 1.12E-05 0.67 -- UGT2B4 
4 rs1500801 169668377 overall 0.000885 1.52 0.00068 1.99 3.96E-06 1.64 ++ PALLD 
5 rs11959975 9902829 overall 0.000229 1.25 0.0067 1.33 5.32E-06 1.27 ++ LOC285692 
5 rs7700462 74332599 overall 0.000224 1.26 0.0234 1.29 1.55E-05 1.27 ++ GCNT4 
5 rs7725038 145388180 overall 9.91E-06 1.34 0.1132 1.20 3.98E-06 1.3 ++ SH3RF2 
5 rs9325001 145393315 overall 9.00E-06 1.34 0.2409 1.14 1.06E-05 1.29 ++ SH3RF2 
6 rs12181583 42154609 overall 6.10E-06 0.8 0.5767 0.95 2.79E-05 0.83 --  
6 rs9369346 42159132 overall 1.13E-07 0.75 0.2948 1.10 5.67E-05 0.83 -+ GUCA1B 
6 rs13217993 42164401 overall 5.33E-06 0.76 0.2594 1.12 0.000858 0.84 -+ GUCA1B 
6 rs6912658 42167161 overall 4.39E-07 0.77 NA NA NA NA NA GUCA1B 
6 rs4424082 42194235 overall 3.32E-07 0.76 0.01507 1.26 0.001433 0.86 -+ MRPS10 
6 rs1871693 136475578 overall 0.000313 0.79 0.04618 0.80 3.85E-05 0.79 -- PDE7B 
6 rs4286796 152681049 overall 3.44E-06 1.30 0.9791 1.00 5.43E-05 1.22 +- SYNE1 
7 rs6961481 25256245 overall 9.84E-06 0.79 0.1371 1.14 0.002531 0.87 -+ NPVF 
11 rs800160 2380134 overall 7.90E-05 1.23 0.00695 1.27 1.91E-06 1.24 ++  
11 rs10840270 9629553 overall 3.34E-05 0.80 0.02075 0.80 2.04E-06 0.8 --  
11 rs17185574 61745694 overall 9.34E-06 0.39 0.3221 1.34 0.002646 0.59 -+  
12 rs9652020 40547379 overall 0.000212 0.80 0.01168 0.77 7.90E-06 0.79 --  
12 rs2873193 133484722 overall 0.000478 1.21 0.03069 1.23 3.79E-05 1.22 ++ CHFR 
17 rs11655073 31736656 overall 6.53E-06 2.02 NA NA NA NA NA ACCN1 
18 rs2111287 54933562 overall 0.000626 0.86 0.04462 1.18 7.23E-05 0.85 --  
18 
 
18 rs7240462 69662581 overall 4.35E-05 0.83 0.06037 0.86 7.51E-06 0.84 --  
1 rs6669271 156738623 pneumococcal 1.05E-06 1.50 0.6652 0.93 2.73E-05 1.37 +-  
1 rs11264997 156752106 pneumococcal 3.81E-06 1.47 0.7004 0.94 7.57E-05 1.34 +-  
1 rs12145401 156761317 pneumococcal 6.03E-06 1.46 0.9775 1.00 5.08E-05 1.35 +-  
1 rs2054991 156772707 pneumococcal 5.06E-06 1.46 0.6475 0.93 0.000102 1.34 +-  
1 rs10908677 156772810 pneumococcal 2.30E-06 1.46 0.6475 0.93 0.000049 1.34 +-  
1 rs923663 156774356 pneumococcal 8.37E-06 1.45 0.6475 0.93 0.00015 1.33 +- OR6Y1 
1 rs863345 156801606 pneumococcal 6.17E-07 1.63 NA NA NA NA NA  
3 rs3913941 21468206 pneumococcal 0.00036 1.39 0.03406 1.45 0.000036 1.4 ++ ZNF659 
3 rs4858325 21468776 pneumococcal 0.00057 1.37 0.04191 1.43 6.44E-05 1.39 ++ ZNF659 
4 rs7661138 156124175 pneumococcal 3.30E-06 1.55 0.01081 0.54 0.000661 1.35 +-  
5 rs6452345 26604000 pneumococcal 6.73E-07 3.70 0.3556 0.39 4.69E-06 3.22 +-  
6 rs1570187 123982387 pneumococcal 8.22E-06 0.71 0.4033 0.89 1.59E-05 0.75 -- TRDN 
7 rs2723392 13395217 pneumococcal 0.00094 1.40 0.01648 1.57 5.14E-05 1.44 ++  
7 rs1347077 13396229 pneumococcal 0.00093 1.40 0.01648 1.57 5.14E-05 1.44 ++  
7 rs17155006 107545079 pneumococcal 0.00017 0.75 0.01443 0.70 7.90E-06 0.74 -- LAMB4 
8 rs3739262 134274895 pneumococcal 2.51E-06 1.63 0.4737 1.17 5.23E-06 1.53 ++ WISP1 
13 rs9526114 45306038 pneumococcal 4.93E-05 1.35 0.04376 1.33 5.83E-06 1.35 ++ LOC283514 
14 rs10483548 38386980 pneumococcal 2.27E-06 1.45 0.5388 0.91 7.56E-05 1.32 +-  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
19 
 
Table S5. The most significant associations (additive model) in the pneumococcal bacteremia discovery analysis after imputation. Imputed discovery analysis (logistic regression 
using the first two principal components as covariates in SNPTEST) included 429 cases with microbiologically proven pneumococcal bacteremia and 2677 controls. All the loci with P 
< 1x10-6 in SNPTEST analysis are included in the table (Only the most significant SNP in each locus plus the ones with replication information available). In addition, SNPs with P < 
1x10-5 are shown, if replication genotyping was available. SNPs highlighted in bold show suggestive association and replication. Replication genotyping was performed using the 
Sequenom iPLEX platform (103 cases and 1333 controls), unless denoted with a * in which case the ImmunoChip was used (113 cases and 1336 controls). OR = odds ratio; “Effects” 
shows the direction of association in the discovery and replication sets   (“+” = minor allele confers a risk; “-“ = minor allele is protective).   
D
ir
e
ct
ly
 
ge
n
o
ty
p
e
d
 
C
H
R
 
B
P
 (
b
3
7
) 
SN
P
 
G
EN
E 
P
 d
is
co
ve
ry
 
im
p
u
te
d
 
O
R
 d
is
co
ve
ry
 
im
p
u
te
d
 
M
A
F 
im
p
u
te
d
 
ca
se
s 
M
A
F 
im
p
u
te
d
 
co
n
tr
o
ls
 
M
A
F 
ge
n
o
ty
p
e
d
 
ca
se
s 
d
is
co
ve
ry
 
M
A
F 
ge
n
o
ty
p
e
d
 
co
n
tr
o
ls
 
d
is
co
ve
ry
 
P
 g
e
n
o
ty
p
e
d
 
d
is
co
ve
ry
 
O
R
 
ge
n
o
ty
p
e
d
 
d
is
co
ve
ry
 
P
 R
e
p
lic
at
io
n
 
O
R
 
R
e
p
lic
at
io
n
 
P
 C
o
m
b
in
e
d
 
O
R
 
C
o
m
b
in
e
d
 
Ef
fe
ct
s 
--- 1 62932815 rs1168000 DOCK7 3.81E-06 2.53 0.0396 0.0183 0.0287 0.0112 3.686E-05 2.81 0.04553 3.10 4.64E-06 2.85 ++ 
--- 1 62953183 rs1168025 DOCK7 3.98E-07 3.07 0.0329 0.0123 0.0276 0.0112 9.211E-05 2.70 0.05296 2.97 1.32E-05 2.74 ++ 
--- 1 158464990 rs11264984 - 3.80E-06 1.41 0.5072 0.4253 0.5266 0.4405 2.851E-06 1.42 0.8489 0.97 4.55E-05 1.31 +- 
YES 1 158471999 rs6669271 - 8.37E-07 1.50 0.2867 0.2092     *0.6652 *0.93 2.73E-05 1.37 +- 
--- 1 158473725 rs6663286 - 2.15E-06 1.45 0.3439 0.2654 0.3338 0.2525 1.996E-06 1.49 0.3933 0.87 9.55E-05 1.34 +- 
YES 1 158485482 rs11264997 - 3.29E-06 1.47 0.2949 0.2219     *0.7004 *0.94 7.57E-05 1.34 +- 
YES 1 158494693 rs12145401 - 5.17E-06 1.45 0.2937 0.2223     *0.9775 *1.00 5.08E-05 1.35 +- 
YES 1 158506083 rs2054991 - 6.30E-06 1.45 0.2937 0.2228     *0.6475 *0.93 0.000102 1.34 +- 
YES 1 158506186 rs10908677 - 2.47E-06 1.46 0.3019 0.2260     *0.6475 *0.93 0.000049 1.34 +- 
YES 1 158507732 rs923663 OR6Y1 6.30E-06 1.45 0.2937 0.2228     *0.6475 *0.93 0.00015 1.33 +- 
YES 1 158518939 rs9804152 OR6Y1 9.00E-06 1.57 0.1539 0.0996     *0.6851 *1.09 4.48E-05 1.45 ++ 
--- 1 158528118 rs10752626 OR6P1 3.11E-07 1.64 0.1906 0.1231 0.1916 0.1216 2.725E-07 1.65 0.6004 1.11 1.17E-06 1.54 ++ 
YES 1 158534982 rs863345 OR6P1 2.10E-07 1.65 0.1946 0.1253 0.1937 0.1241 3.766E-07 1.65 0.506 1.15 1.14E-06 1.55 ++ 
--- 3 128701130 rs6439153 KIAA1257 4.71E-07 3.72 0.0251 0.0077 0.0413 0.0225 0.0001585 2.18 0.000608 3.02 4.99E-07 2.39 ++ 
YES 4 155904725 rs7661138 - 3.02E-06 1.54 0.2133 0.1526     *0.01081 *0.54 0.000661 1.35 +- 
YES 5 26568243 rs6452345 - 8.26E-08 3.70 0.0280 0.0075     *0.3556 *0.39 4.69E-06 3.22 +- 
--- 5 169453092 rs114183953 DOCK2 1.95E-07 3.15 0.0335 0.0111 0.0337 0.0108 8.934E-07 3.19 0.562 1.36 2.34E-06 2.77 ++ 
--- 5 169460440 rs138715413 DOCK2 1.81E-07 3.16 0.0334 0.0109 0.0323 0.0110 3.778E-06 3.00 0.5461 1.38 8.06E-06 2.63 ++ 
YES 6 38520864 rs724242 BTBD9 8.76E-06 0.64 0.1539 0.2185     *0.91 *0.98 0.000121 0.72 -- 
YES 6 123940688 rs1570187 TRDN 7.49E-06 0.71 0.4114 0.4836     *0.4033 *0.89 1.59E-05 0.75 -- 
--- 7 13394635 rs188755755 - 8.91E-09 2.72 0.0593 0.0220 0.0544 0.0214 1.039E-06 2.50 0.01096 2.40 3.73E-08 2.47 ++ 
--- 7 13396630 rs140817150 - 7.25E-09 2.74 0.0592 0.0217 0.0639 0.0266 3.585E-07 2.39 0.001161 2.72 1.69E-09 2.47 ++ 
--- 7 13401014 rs116432683 - 7.20E-09 2.74 0.0592 0.0217          
--- 8 134193074 rs11782936 - 5.80E-07 1.65 0.2035 0.1404          
YES 8 134205713 rs3739262 WISP1 1.98E-06 1.63 0.1667 0.1087     *0.4737 *1.17 5.23E-06 1.53 ++ 
YES 9 27773059 rs775397 - 8.98E-06 1.46 0.2622 0.1946     *0.8725 *1.03 0.000057 1.36 ++ 
--- 14 39314125 rs7142347 - 3.69E-07 1.74 0.1475 0.0963          
--- 14 39315768 rs73277180 - 4.71E-07 1.73 0.1470 0.0961 0.1396 0.0966 6.451E-05 1.56 0.9459 1.02 0.000224 1.46 ++ 
YES 14 39317229 rs10483548 - 1.96E-06 1.45 0.3835 0.3106     *0.5388 *0.91 7.56E-05 1.32 +- 
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Table S6. The most significant associations in the chr7 lincRNA region in the pneumococcal bacteremia discovery analysis (after Affymetrix SNP 6.0 genotyping and 
imputation). Directly genotyped SNPs with P-values less than 0.05 and imputed SNPs with P-value less than 1x10-6 are shown in the region (250 kb region flanking the top 
SNP rs140817150 is shown). * denotes imputed SNPs that were confirmed by direct genotyping using Sequenom. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP 
BP (b37) in    
chr 7 
genotyped(G)/
imputed (I) 
P discovery 
OR 
discovery 
maf 
cases 
maf 
controls 
Position relative to 
AC011288.2-001 
Position relative to 
AC006000.5 
rs6973224 13266540 G 0.043 1.17 0.371 0.340 intron 2-3 3' downstream 
rs17166908 13270959 G 0.0037 0.78 0.223 0.273 intron 2-3 3' downstream 
rs10230302 13275542 G 0.0016 1.33 0.220 0.170 intron 2-3 3' downstream 
rs183536610 13350258 I 2.05E-07 2.42 0.061 0.027 intron 3-4 3' downstream 
rs114563489 13351620 I 1.76E-07 2.44 0.061 0.026 intron 3-4 3' downstream 
rs114237419 13352333 I 1.62E-07 2.44 0.061 0.026 intron 3-4 3' downstream 
rs184608123 13355876 I 1.15E-07 2.48 0.061 0.026 intron 3-4 3' downstream 
rs112384903 13356316 I 1.12E-07 2.48 0.061 0.026 intron 3-4 3' downstream 
rs75811201 13360996 I 9.13E-08 2.50 0.061 0.025 intron 3-4 3' downstream 
rs75208382 13363234 I 1.42E-07 2.51 0.059 0.024 intron 3-4 3' downstream 
rs192359699 13365219 I 5.45E-08 2.55 0.061 0.025 intron 3-4 3' downstream 
rs184746152 13371007 I 4.31E-08 2.57 0.060 0.024 intron 3-4 3' downstream 
rs75091393 13373716 I 4.14E-08 2.58 0.060 0.024 intron 3-4 3' downstream 
rs139819665 13374686 I 4.11E-08 2.58 0.060 0.024 intron 3-4 3' downstream 
rs186811037 13377949 I 4.10E-08 2.58 0.060 0.024 intron 3-4 3' downstream 
rs182261263 13378675 I 4.08E-08 2.58 0.060 0.024 intron 3-4 3' downstream 
rs146813781 13380872 I 4.07E-08 2.58 0.060 0.024 intron 3-4 intron 3-4 
rs182683147 13385227 I 4.04E-08 2.58 0.060 0.024 intron 3-4 intron 3-4 
rs74757989 13386451 I 4.04E-08 2.58 0.060 0.024 intron 3-4 intron 3-4 
rs78571337 13387037 I 4.03E-08 2.58 0.060 0.024 intron 3-4 intron 3-4 
rs186096483 13387766 I 4.01E-08 2.58 0.060 0.024 intron 3-4 intron 3-4 
rs116118621 13391291 I 1.08E-08 2.70 0.059 0.022 intron 3-4 intron 3-4 
rs188755755* 13394635 I 8.91E-09 2.72 0.059 0.022 intron 3-4 intron 3-4 
rs140817150* 13396630 I 7.25E-09 2.74 0.059 0.022 intron 3-4 intron 3-4 
rs116432683 13401014 I 7.20E-09 2.74 0.059 0.022 intron 3-4 intron 3-4 
rs114325568 13423766 I 1.43E-07 2.44 0.062 0.026 intron 3-4 5' upstream 
rs2568600 13424671 G 0.0012 1.39 0.171 0.131 intron 3-4 5' upstream 
rs2723392 13428692 G 0.00097 1.40 0.175 0.133 intron 3-4 5' upstream 
rs1347077 13429704 G 0.00097 1.40 0.175 0.133 intron 3-4 5' upstream 
rs77922834 13432361 I 1.06E-08 2.70 0.061 0.023 intron 3-4 5' upstream 
rs192669340 13471405 I 2.66E-08 2.49 0.068 0.029 intron 3-4 5' upstream 
rs184390046 13476586 I 1.79E-08 2.70 0.058 0.023 intron 3-4 5' upstream 
rs10807764 13478678 G 0.0061 1.28 0.223 0.177 intron 3-4 5' upstream 
rs17167126 13480033 G 0.00014 1.43 0.193 0.139 intron 3-4 5' upstream 
rs2217612 13483120 G 0.0029 1.35 0.172 0.129 intron 3-4 5' upstream 
rs17167140 13484133 G 0.001827 1.38 0.171 0.127 intron 3-4 5' upstream 
rs17167142 13484328 G 0.001568 1.38 0.171 0.127 intron 3-4 5' upstream 
rs1432488 13484508 G 0.00209 1.37 0.171 0.128 intron 3-4 5' upstream 
rs10247084 13485416 G 0.003145 1.33 0.185 0.143 intron 3-4 5' upstream 
rs1432492 13501571 G 0.015065 1.23 0.256 0.213 intron 3-4 5' upstream 
rs12699509 13561595 G 0.013637 1.34 0.114 0.090 intron 3-4 5' upstream 
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Table S7. Comparison of association statistics after imputation and direct genotyping of discovery and replication samples. As described in the Methods section, only siblings (and 
more related individuals) were excluded from the main analysis. Association statistics of the following analyses are shown: the imputed discovery main analysis (SNPTEST2; 
frequentist method score, the first two principal components as covariates), directly genotyped discovery and replication analyses (PLINK, 2 PCA components as covariates), directly 
genotyped discovery and replication analyses when a mixed model (MM) was used to better account for relatedness and underlying population structure (with siblings and more 
distant relatives included and with all second degree and more closely related individuals (r>0.2) excluded from the analysis). Number of bacteremia cases overall (cases B), 
pneumococcal cases (cases P), and controls included in each analysis are indicated in each column. The chromosome 7 lincRNA hit in the pneumococcal subgroup (SNPs 
rs188755755 and rs140817150) reached genome-wide significance in the additive model in all of these analyses. MM =mixed model; B = bacteremia overall; P = pneumococcal 
bacteremia. 
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MM Discovery 
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(Genotyped; 
all related 
(r>0.2) 
removed) 
 
cases B: 404 
cases P: 102 
controls:131
1 
MM Combined 
(Genotyped; all 
related (r>0.2) 
removed) 
 
cases B: 1880 
cases P: 510 
controls: 3854 
P OR P OR P OR P OR P OR P OR P OR P OR P OR P OR 
3 51009435 rs9879725 B 2.4E-08 0.71 6.9E-08 0.71 0.5085 1.07 1.6E-05 0.79 8.0E-08 0.72 0.3019 1.11 4.0E-05 0.80 0.02839 0.80 0.947 1.01 0.0564 0.84 
3 51390967 rs13353505 B 3.8E-06 0.64 3.2E-05 0.67 0.9783 1.00 0.0004 0.75 8.4E-05 0.70 0.8907 1.02 0.00095 0.77 0.00832 0.66 0.891 1.04 0.0272 0.74 
6 42162388 rs3749921 B 7.9E-08 0.74 2.3E-07 0.75 0.1653 1.14 0.0002 0.83 4.1E-07 0.76 0.1525 1.14 0.00028 0.84 0.01349 0.80 0.414 1.15 0.0771 0.87 
6 42181960 rs1884318 B 4.4E-08 0.74 3.9E-07 0.75 0.1632 1.14 0.0002 0.84 7.2E-07 0.76 0.1501 1.14 0.0004 0.85 0.0155 0.80 0.412 1.15 0.0848 0.87 
6 42184400 rs13197564 B 5.3E-08 0.74 1.6E-07 0.75 0.1493 1.15 0.0002 0.83 3.2E-07 0.76 0.1416 1.14 0.00025 0.84 0.01139 0.80 0.474 1.13 0.0601 0.86 
6 152678110 rs6906442 B 3.6E-06 1.35 3.2E-05 1.32 0.536 1.08 8.1E-05 1.26 5.8E-05 1.30 0.6408 1.06 0.00017 1.24 0.06383 1.22 0.738 0.93 0.1268 1.16 
6 152679729 rs9478326 B 2.3E-06 1.30 1.9E-05 1.27 0.8464 1.02 0.0001 1.20 6.3E-05 1.24 0.9014 1.01 0.00038 1.18 0.04085 1.20 0.587 0.91 0.1122 1.14 
12 9350854 rs74500107 B 8.1E-08 1.80 3.3E-07 1.68 0.3738 0.85 4.7E-05 1.44 8.0E-07 1.63 0.3668 0.84 7.9E-05 1.41 0.0763 1.36 0.685 0.87 0.1621 1.24 
12 9358781 rs149632973 B 4.1E-07 1.75 2.8E-06 1.70 0.3227 0.82 0.0003 1.43 9.9E-06 1.63 0.3286 0.82 0.0006 1.39 0.14336 1.33 0.883 0.95 0.2233 1.23 
1 62932815 rs1168000 P 3.8E-06 2.53 3.7E-05 2.81 0.0455 3.10 4.6E-06 2.85 3.0E-05 2.76 0.0463 2.90 4.6E-06 2.79 8.5E-05 2.65 0.041 2.99 1.2E-05 2.70 
1 62953183 rs1168025 P 4E-07 3.07 9.2E-05 2.70 0.053 2.97 1.3E-05 2.74 8.2E-05 2.64 0.0541 2.78 1.4E-05 2.66 0.00022 2.53 0.049 2.85 3.4E-05 2.58 
1 158464990 rs11264984 P 3.8E-06 1.41 2.9E-06 1.42 0.8489 0.97 4.6E-05 1.31 7.2E-07 1.45 0.8720 0.98 2.1E-05 1.33 1.5E-06 1.44 0.868 0.98 3.8E-05 1.32 
1 158473725 rs6663286 P 2.2E-06 1.45 2E-06 1.49 0.3933 0.87 9.6E-05 1.34 1.9E-06 1.47 0.4061 0.87 0.00011 1.33 6.8E-07 1.50 0.433 0.88 5.4E-05 1.35 
1 158528118 rs10752626 P 3.1E-07 1.64 2.7E-07 1.65 0.6004 1.11 1.2E-06 1.54 7.6E-08 1.68 0.6203 1.11 6.2E-07 1.55 2.8E-07 1.66 0.627 1.10 1.9E-06 1.53 
1 158534982 rs863345 P 2.1E-07 1.65 3.8E-07 1.65 0.506 1.15 1.1E-06 1.55 1.1E-07 1.68 0.5136 1.14 5.8E-07 1.56 3.7E-07 1.65 0.520 1.14 1.7E-06 1.54 
5 169453092 rs114183953 P 1.9E-07 3.15 8.9E-07 3.19 0.562 1.36 2.3E-06 2.77 1.7E-07 3.39 0.6620 1.24 1.4E-06 2.82 4.1E-07 3.34 0.592 1.31 2.3E-06 2.79 
5 169460440 rs138715413 P 1.8E-07 3.16 3.8E-06 3.00 0.5461 1.38 8.1E-06 2.63 1.0E-06 3.16 0.6367 1.27 5.2E-06 2.67 2.2E-06 3.11 0.569 1.33 8.6E-06 2.64 
7 13394635 rs188755755 P 8.9E-09 2.72 1E-06 2.50 0.011 2.40 3.7E-08 2.47 2.6E-07 2.57 0.0060 2.59 9.2E-09 2.58 1.7E-07 2.65 0.004 2.72 4.6E-09 2.67 
7 13396630 rs140817150 P 7.3E-09 2.74 3.6E-07 2.39 0.0012 2.72 1.7E-09 2.47 9.7E-08 2.45 0.0005 2.96 5.1E-10 2.55 3.6E-08 2.56 3E-4 3.06 1.5E-10 2.66 
14 39315768 rs73277180 P 4.7E-07 1.73 6.5E-05 1.56 0.9459 1.02 0.0002 1.46 9.7E-05 1.54 0.9666 0.99 0.00044 1.43 0.0001 1.54 0.962 0.99 0.0005 1.43 
16 26762549 rs142637346 P 1.28E-06 2.36 3.7E-06 2.37 0.5861 1.25 9.2E-06 2.13 1.8E-06 2.38 0.5383 1.29 5.3E-06 2.15 2.7E-06 2.37 0.563 1.27 8.2E-06 2.13 
16 26775675 rs140127109 P 1.07E-06 2.37 4.2E-06 2.36 0.6124 1.23 1.1E-05 2.11 2.0E-06 2.37 0.5656 1.27 6.1E-06 2.14 2.8E-06 2.37 0.591 1.25 9.1E-06 2.12 
16 26786471 rs148926738 P 1.11E-06 2.35 8.9E-05 2.16 0.3186 1.47 8.1E-05 2.00 6.1E-05 2.17 0.2866 1.50 5.7E-05 2.01 0.0001 2.14 0.306 1.48 9.7E-05 1.98 
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Table S8. The most significant associations (additive and genotypic models) in the bacteremia overall discovery analysis after imputation. Imputed discovery analysis (logistic 
regression using the first two principal components as covariates in SNPTEST) included 1536 cases with microbiologically proven bacteremia and 2677 controls. All the loci with p< 
1x10-6 in the SNPTEST analysis are included in the table (Only the most significant SNP in the locus plus the ones with replication information available are shown). In addition, SNPs 
with <1x10-5 are shown, if replication genotyping was available. SNPs highlighted in bold show suggestive association and replication. Replication genotyping was performed using 
the Sequenom iPlex platform (407 cases and 1333 controls), unless denoted with * in which case the ImmunoChip was used (434 cases and 1336 controls).  Only the additive model 
is shown if both of the models passed the criteria described above. OR = odds ratio; “Effects” shows the direction of association in the discovery and replication sets (“+” = minor 
allele confers a risk; “-“ = minor allele is protective). 
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YES 1 30169447 rs11808436  3.58E-06 1.25 0.359 0.309     *0.2624 *0.91 0.0005 1.16 +- Additive 
--- 2 31300106 rs17010685 GALNT14 2.27E-07 2.18 0.031 0.017 0.043 0.035 0.04829 1.26 0.1479 0.70 0.25224 1.13 +- Additive 
YES 2 31539280 rs207413  1.09E-06 1.58 0.076 0.051     *0.9735 *0.99 1.8E-05 1.44 +- Additive 
YES 3 50998816 rs9869826 DOCK3 2.30E-08 0.71 0.150 0.202     *0.7553 *1.03 4.4E-06 0.79 -+ Additive 
--- 3 51009435 rs9879725 DOCK3 2.36E-08 0.71 0.151 0.203 0.147 0.196 6.9E-08 0.71 0.5085 1.07 1.6E-05 0.79 -+ Additive 
--- 3 51390967 rs13353505 DOCK3 3.84E-06 0.64 0.054 0.080 0.057 0.082 3.2E-05 0.67 0.9783 1.00 0.00037 0.75 -+ Additive 
--- 3 53783784 rs898420 CACNA1D 4.25E-07 1.28 0.384 0.342          Additive 
YES 3 62138954 rs7633054 PTPRG 1.18E-06 1.38 0.151 0.110     *0.04803 *1.27 1.5E-07 1.36 ++ Additive 
YES 3 62157762 rs9853409 PTPRG 2.95E-06 1.34 0.174 0.135     *0.3831 *1.10 8.4E-06 1.28 ++ Additive 
--- 3 62160653 rs17066238 PTPRG 2.96E-06 1.45 0.109 0.078 0.116 0.091 0.00022 1.33 0.8184 0.97 0.00186 1.23 +- Additive 
YES 6 42154609 rs12181583 GUCA1B 5.89E-06 1.25 0.253 0.301     *0.5767 *0.95 2.8E-05 0.83 -- Additive 
YES 6 42159132 rs9369346 GUCA1B 1.18E-07 0.75 0.208 0.264     *0.2948 *1.10 5.7E-05 0.83 -+ Additive 
--- 6 42162388 rs3749921 GUCA1B 7.90E-08 0.74 0.201 0.257 0.202 0.257 2.3E-07 0.75 0.1653 1.14 0.00017 0.83 -+ Additive 
YES 6 42164401 rs13217993 GUCA1B 3.92E-06 0.76 0.169 0.217     *0.2594 *1.12 0.00086 0.84 -+ Additive 
--- 6 42181960 rs1884318 MRPS10 4.35E-08 0.74 0.200 0.257 0.202 0.257 3.9E-07 0.75 0.1632 1.14 0.00024 0.84 -+ Additive 
--- 6 42184400 rs13197564 MRPS10 5.29E-08 0.74 0.207 0.264 0.208 0.264 1.6E-07 0.75 0.1493 1.15 0.00015 0.83 -+ Additive 
YES 6 42194235 rs4424082 MRPS10 2.74E-07 0.76 0.205 0.261     *0.01507 *1.26 0.00143 0.86 -+ Additive 
--- 6 152672540 rs4632900 SYNE1 2.96E-08 1.41 0.188 0.145          Additive 
--- 6 152678110 rs6906442 SYNE1 3.57E-06 1.35 0.163 0.129 0.148 0.117 3.2E-05 1.32 0.536 1.08 8.1E-05 1.26 ++ Additive 
--- 6 152679729 rs9478326 SYNE1 2.25E-06 1.30 0.232 0.189 0.239 0.199 1.9E-05 1.27 0.8464 1.02 0.00013 1.20 ++ Additive 
YES 6 152681049 rs4286796 SYNE1 3.30E-06 1.30 0.221 0.179     *0.9791 *1.00 5.4E-05 1.22 +- Additive 
--- 12 9322394 rs75698727 PZP 2.92E-08 1.78 0.066 0.038          Additive 
--- 12 9350854 rs74500107 PZP 8.06E-08 1.80 0.060 0.035 0.067 0.039 3.3E-07 1.68 0.3738 0.85 4.7E-05 1.44 +- Additive 
--- 12 9358781 rs149632973 PZP 4.10E-07 1.75 0.057 0.034 0.055 0.033 2.8E-06 1.70 0.3227 0.82 0.00028 1.43 +- Additive 
--- 16 12323566 rs830715 SNX29 6.75E-07 1.29 0.300 0.251          Additive 
--- 10 67559700 rs16921870  7.94E-07 NA 0.094 0.079          Genotypic 
YES 10 67560490 rs10509235  8.23E-07 NA 0.095 0.079     *0.0255     Genotypic 
YES 11 5029457 rs11035102 HBB 6.93E-08 NA 0.245 0.245     *0.2618     Genotypic 
--- 11 5273865 rs113892119 HBB 5.08E-13 NA 0.096 0.093 0.083 0.085 3.42E-12 NA 0.00178 NA NA NA  Genotypic 
--- 11 5252794 rs12295158 HBB 1.32E-10 NA 0.124 0.132 0.123 0.129 2.89E-08 NA 0.2385 NA NA NA  Genotypic 
--- 11 5248232 rs334 HBB 1.33E-10 NA 0.136 0.129 0.087 0.085 4.09E-11 NA 0.00077 NA NA NA  Genotypic 
 
